Soleno Therapeutics Inc [SLNO] stock prices are up 3.18% to $46.73 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SLNO shares have gain 0.15% over the last week, with a monthly amount glided 10.19%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on May 10, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $72. Previously, Piper Sandler started tracking the stock with Overweight rating on February 05, 2024, and set its price target to $93. On January 23, 2024, Stifel initiated with a Buy rating and assigned a price target of $63 on the stock. Guggenheim initiated its recommendation with a Buy and recommended $8 as its price target on September 29, 2020. Craig Hallum started tracking with a Buy rating for this stock on January 10, 2020, and assigned it a price target of $8. In a note dated December 23, 2019, Oppenheimer initiated an Outperform rating and provided a target price of $10 on this stock.
The stock price of Soleno Therapeutics Inc [SLNO] has been fluctuating between $3.69 and $53.82 over the past year. Currently, Wall Street analysts expect the stock to reach $82.5 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $46.73 at the most recent close of the market. An investor can expect a potential return of 76.55% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at -15.59%, Pretax Profit Margin comes in at -15.1%, and Net Profit Margin reading is -15.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.62 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.18 points at the first support level, and at 41.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.19, and for the 2nd resistance point, it is at 49.66.
Ratios To Look Out For
It’s worth pointing out that Soleno Therapeutics Inc [NASDAQ:SLNO]’s Current Ratio is 11.23. As well, the Quick Ratio is 11.23, while the Cash Ratio is 3.18.
Transactions by insiders
Recent insider trading involved Anish Bhatnagar, CHIEF EXECUTIVE OFFICER, that happened on Jul 01 ’24 when 19256.0 shares were sold. CHIEF FINANCIAL OFFICER, Mackaness James H completed a deal on Jul 01 ’24 to sell 7190.0 shares. Meanwhile, Yen Kristen sold 2170.0 shares on Jul 01 ’24.
